Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients

Reuters

01/12

<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients

Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602851415"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602851415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602851415?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602851415","market":"nz","top_or_hot":-1,"title":"Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5TgZPP:1","article_id":"2602851415","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602851415","pubTimestamp":1768219379,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","VKTX":"Viking Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4599":"减肥药"},"translate_title":"Viking Therapeutics报告2期试验显示VK2735可使肥胖患者体重减轻高达14.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n    \n\n        Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}